A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

被引：6
|
作者：
Jhaveri, Komal [1 ]
Juric, Dejan [2 ]
Saura, Cristina [3 ]
Cervantes, Andres [4 ]
Melnyk, Anton [5 ]
Patel, Manish R. [6 ]
Oliveira, Mafalda [3 ]
Gambardella, Valentina [4 ]
Ribrag, Vincent [7 ]
Ma, Cynthia X. [8 ]
Aljumaily, Raid [9 ]
Bedard, Philippe L. [10 ]
Sachdev, Jasgit C. [11 ]
Bond, John [12 ]
Jones, Surai [12 ]
Wilson, Timothy R. [12 ]
Wei, Michael C. [12 ]
Baselga, Jose [1 ]
机构：
[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain
[4] Univ Valencia, Inst Hlth Res INCLIVA, CIBERONC, Valencia, Spain
[5] Texas Oncol Abilene, Abilene, TX USA
[6] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[7] Inst Gustave Roussy, Villejuif, France
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[10] Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] TGen, Honor Hlth Res Inst, Scottsdale, AZ USA
[12] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT046
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Edgar, Kyle A.
    Song, Kyung
    Schmidt, Stephen
    Kirkpatrick, Don
    Phu, Lilian
    Nannini, Michelle
    Hong, Rebecca
    Cheng, Eric
    Young, Amy
    Sampath, Deepak
    Friedman, Lori S.
    CANCER RESEARCH, 2016, 76
  • [3] ABSORPTION, METABOLISM, AND EXCRETION OF TASELISIB (GDC-0032), A PI3K INHIBITOR, IN RATS, DOGS, AND HUMANS
    Ma, Shuguang
    Salphati, Laurent
    Srikumar, Srikumar
    Takahashi, Ryan
    Ding, Xiao
    Pang, Jodie
    Wang, Bing
    Remarchuk, Travis
    Hsu, Jerry
    Hop, Cornelis
    Ware, Joseph A.
    Khojasteh, S. Cyrus
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S74 - S75
  • [4] Part II: Development of a manufacturing route to PI3K β-sparing inhibitor GDC-0032 (Taselisib)
    Remarchuk, Travis
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [5] Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
    Edgar, Kyle A.
    Nannini, Michelle
    Hong, Rebecca
    Eigenbrot, Charlie
    Schmidt, Stephen
    Young, Amy
    Sampath, Deepak
    Wallin, Jeffrey J.
    Friedman, Lori S.
    CANCER RESEARCH, 2015, 75
  • [6] Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
    Olivero, Alan G.
    Heffron, Timothy P.
    Baumgardner, Matthew
    Belvin, Marcia
    Ross, Leanne Berry
    Blaquiere, Nicole
    Bradley, Erin
    Castanedo, Georgette
    Derynck, Mika
    Do, Steven
    Dotson, Jennafer
    Dudley, Danette
    Edgar, Kyle
    Folkes, Adrian
    Francis, Ross
    Gianetti, Tony
    Goldsmith, Richard
    Goldsmith, Paul
    Guan, Jane
    Harrison, Trevor
    Heald, Robert
    Hsu, Jerry
    Jackson, Phillip
    Jones, Graham
    Kim, Amy
    Kolesnikov, Aleks
    Lackner, Mark
    Lee, Leslie
    Lesnick, John
    Lewis, Cristina
    Mamounas, Michael
    McLean, Neville
    Murray, Jeremy
    Ndubaku, Chudi
    Nonomiya, Jim
    Pang, Jodie
    Pegg, Neil
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepack
    Sideris, Stephen
    Siu, Michael
    Staben, Steven
    Sutherlin, Daniel
    Ultsch, Mark
    Wallin, Jeff
    Wang, Lan
    Wiesmann, Christian
    Zhang, Xiaolin
    Friedman, Lori S.
    CANCER RESEARCH, 2013, 73 (08)
  • [7] GDC-0032, a p110 beta sparing PI3K inhibitor is highly efficient on PIK3CA-mutated and HER2-amplified breast cancer model
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Williams, Casey
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2017, 77
  • [8] ASSESSMENT OF ABSOLUTE BIOAVAILABILITY AND MASS BALANCE OF THE PI3K INHIBITOR TASELISIB (GDC-0032) IN HEALTHY SUBJECTS.
    Sahasranaman, S.
    Ma, S.
    Hsu, J.
    Gates, M.
    Ran, Y.
    Zhang, K.
    Yehl, P.
    Salphati, L.
    Ding, X.
    Bradford, D.
    Dresser, M.
    Ware, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81
  • [9] Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
    Zumsteg, Zachary S.
    Morse, Natasha
    Krigsfeld, Gabriel
    Gupta, Gaorav
    Higginson, Daniel S.
    Lee, Nancy Y.
    Morris, Luc
    Ganly, Ian
    Shiao, Stephan L.
    Powell, Simon N.
    Chung, Christine H.
    Scaltriti, Maurizio
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 2009 - 2019
  • [10] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors
    Baselga, Jose
    Cortes, Javier
    DeLaurentils, Michelino
    Dent, Susan
    Dieras, Veronique
    Harbeck, Nadia
    Hsu, Jerry Y.
    Jin, Huan
    Schimmoller, Frauke
    Wilson, Timothy R.
    Im, Young-Hyuck
    Jacot, William
    Krop, Ian E.
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345